Imperial College London

DrRichardNicholas

Faculty of MedicineDepartment of Brain Sciences

Professor of Practice (Neurology)
 
 
 
//

Contact

 

r.nicholas

 
 
//

Location

 

12L12CLab BlockCharing Cross Campus

//

Summary

 

Publications

Publication Type
Year
to

232 results found

Giannetti P, Politis M, Su P, Turkheimer FE, Malik O, Keihaninejad S, Wu K, Reynolds R, Nicholas R, Piccini Pet al., 2012, PK11195-PET Enhancement in Black Holes Correlates with Disability and Outcome in Progressive Multiple Sclerosis, 137th Annual Meeting of the American-Neurological-Association (ANA), Publisher: WILEY-BLACKWELL, Pages: S112-S112, ISSN: 0364-5134

Conference paper

Giannetti P, Niccolini F, Nicholas R, 2012, BG-12 and its potential for the prevention of relapse in multiple sclerosis., Degener Neurol Neuromuscul Dis, Vol: 2, Pages: 119-132

Multiple sclerosis (MS) arises from an immune attack on the central nervous system producing demyelination and axonal loss. Clinically the relapsing-remitting course is characterized by subacute onset of neurological symptoms usually with partial or complete recovery, while the progressive course, predominant in the later stages, is characterized by progressive disability in the absence of relapses. A number of disease-modifying treatments have been developed and are increasingly effective at targeting relapses. Early injectable therapies such as interferon and glatiramer acetate are only partially effective, but have a good safety record. Recently, natalizumab, an intravenous therapy, demonstrated increased effectiveness, but side effects complicate its use. The first oral therapy offering good efficacy and convenience, fingolimod, was approved in USA in 2010 and Europe in 2011. BG-12 is a potential novel oral therapy for MS, which has previously been used as a different formulation for psoriasis. It has anti-inflammatory and neuroprotective actions in vitro, which makes it a promising candidate for future therapies. Phase II studies showed that BG-12 reduced MRI inflammatory activity over placebo, which was confirmed in two Phase III studies indicating immune modulation may be its principal action rather than neuroprotection. In these studies, BG-12 reduced relapse rates consistently with variable effects on progression and few serious adverse events. With its favorable efficacy-tolerability profile, BG-12 could offer a substantial step forward for the care for subjects affected by relapsing MS.

Journal article

Thapar A, Lane TRA, Nicholas R, 2012, Chronic Cerebrospinal Venous Insufficiency: It is an entity and a subset of multiple sclerosis - Against The Motion, Vascular and Endovascular Controversies Update, Editors: Greenhalgh, Publisher: BIBA Medical, Pages: 696-705

Book chapter

Kamel F, Ettorre A, Durrenberger PF, Malik O, Nicholas R, Boyton R, Altmann Det al., 2011, Altered invariant natural killer T cells in multiple sclerosis, Annual Congress of the British-Society-for-Immunology, Publisher: WILEY-BLACKWELL, Pages: 41-41, ISSN: 0019-2805

Conference paper

Thapar A, Lane T, Nicholas R, Friede T, Ellis M, Assenheim J, Franklin IJ, Davies AHet al., 2011, Systematic review of sonographic chronic cerebrospinal venous insufficiency findings in multiple sclerosis, PHLEBOLOGY, Vol: 26, Pages: 319-325, ISSN: 0268-3555

Journal article

Ettorre A, Kamel FO, Durrenberger PF, Traherne J, Giannetti P, Malik O, Nicholas R, Trowsdale J, Boyton RJ, Altmann DMet al., 2011, KIR expression as a biomarker of multiple sclerosis disease type, Annual Congress of the British-Society-for-Immunology, Publisher: WILEY-BLACKWELL, Pages: 172-172, ISSN: 0019-2805

Conference paper

Howell O, Reeves C, Nicholas R, Carassiti D, Roncaroli F, Magliozzi R, Aloisi F, Gveric D, Reynolds Ret al., 2011, Meningeal inflammation is widespread and linked to cortical pathology and an accelerated clinical course in secondary progressive multiple sclerosis, MULTIPLE SCLEROSIS JOURNAL, Vol: 17, Pages: S39-S39, ISSN: 1352-4585

Journal article

Wilkie D, Chataway J, Nicholas R, 2011, Regulation and oversight of independent investigator-led multiple sclerosis (MS) studies results in a 10-fold greater administrative workload for independent investigators compared to being an investigator in a pharmaceutical company-led MS trial, MULTIPLE SCLEROSIS JOURNAL, Vol: 17, Pages: S466-S466, ISSN: 1352-4585

Journal article

Mattoscio M, Nicholas R, Malik O, Dazzi F, Muraro PAet al., 2011, Differential increase of circulating haematopoietic stem cells following therapeutic alpha 4-integrin blockade in multiple sclerosis: definition of mobilisers versus non-mobilisers subjects and clinical correlations, MULTIPLE SCLEROSIS JOURNAL, Vol: 17, Pages: S191-S191, ISSN: 1352-4585

Journal article

Nicholas R, Straube S, Schmidli H, Schneider S, Friede Tet al., 2011, Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design, MULTIPLE SCLEROSIS JOURNAL, Vol: 17, Pages: 1211-1217, ISSN: 1352-4585

Journal article

Thapar A, Lane TRA, Pandey V, Shalhoub J, Malik O, Ellis M, Franklin IJ, Nicholas R, Davies AHet al., 2011, Internal jugular thrombosis post venoplasty for chronic cerebrospinal venous insufficiency, PHLEBOLOGY, Vol: 26, Pages: 254-256, ISSN: 0268-3555

Journal article

Chataway J, Awad M, Meadmore K, Alsanousi A, Frost C, Chandler K, Merrick K, Wilkie D, Nicholas R, Chan Det al., 2011, COGNITIVE AND NEUROPSYCHIATRIC STATUS IN A LARGE COHORT OF PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol: 82, ISSN: 0022-3050

Journal article

Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, Serafini B, Aloisi F, Roncaroli F, Magliozzi R, Reynolds Ret al., 2011, Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis, BRAIN, Vol: 134, Pages: 2755-2771, ISSN: 0006-8950

Journal article

Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell Oet al., 2011, The neuropathological basis of clinical progression in multiple sclerosis, ACTA NEUROPATHOLOGICA, Vol: 122, Pages: 155-170, ISSN: 0001-6322

Journal article

Bentley P, Wang T, Malik O, Nicholas R, Ban M, Sawcer S, Sharma Pet al., 2011, CADASIL with cord involvement associated with a novel and atypical NOTCH3 mutation, JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol: 82, Pages: 855-860, ISSN: 0022-3050

Journal article

Friede T, Parsons N, Stallard N, Todd S, Marquez EV, Chataway J, Nicholas Ret al., 2011, Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis, 6th International Meeting on Statistical Methods in Biopharmacy, Publisher: WILEY, Pages: 1528-1540, ISSN: 0277-6715

Conference paper

Giannetti P, Politis M, Su P, Turkheimer F, Wu K, Reynolds R, Nicholas R, Piccini Pet al., 2011, Two different roles for microglia in vivo in T1 black holes in relapsing and progressive multiple sclerosis?, 21st Meeting of the European-Neurological-Society, Publisher: SPRINGER HEIDELBERG, Pages: 221-221, ISSN: 0340-5354

Conference paper

Wakerley BR, Nicholas RS, Malik OR, Altmann DMet al., 2011, The Effects of Disease Activity and Interferon-beta on Telomere Length and Telomerase Activity in Multiple Sclerosis, 63rd AAN Annual Meeting, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: A135-A135, ISSN: 0028-3878

Conference paper

Howell OW, Reeves C, Carassiti D, Nicholas R, Radotra B, Gentleman S, Roncaroli F, Aloisi F, Magliozzi R, Reynolds Ret al., 2011, The distribution of B-cell follicle-like structures in the cerebral meninges and their association with extensive inflammation and demyelination in multiple sclerosis, 112th Meeting of the British-Neuropathological-Society, Publisher: WILEY-BLACKWELL PUBLISHING, INC, Pages: 27-27, ISSN: 0305-1846

Conference paper

Chataway J, Nicholas R, Todd S, Miller DH, Parsons N, Valdes-Marquez E, Stallard N, Friede Tet al., 2011, A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis, MULTIPLE SCLEROSIS JOURNAL, Vol: 17, Pages: 81-88, ISSN: 1352-4585

Journal article

Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PAet al., 2011, Development of oral immunomodulatory agents in the management of multiple sclerosis., Drug Des Devel Ther, Vol: 5, Pages: 255-274

The emergence of oral disease-modifying therapies in multiple sclerosis (MS) will have a significant impact on the evolving scenario of immunomodulatory treatments in MS where current therapies are all injectable. Reducing relapses in trials translates for individuals with MS into a therapeutic aim of stopping future events. Thus the possible absence of any perceived benefits to the individual together with the long disease course, variable outcome, and a younger age group affected in MS makes side effects the major issue. The use of disease-modifying therapies as a whole needs to be placed in the context of a widening therapeutic indication where the use of these therapies is being justified at an increasingly early stage and in pre-MS syndromes such as clinically isolated and radiologically isolated syndromes where no fixed disability is likely to have accumulated. The five oral therapies discussed (cladribine, fingolimod, laquinimod, BG-12, and teriflunomide) have just completed Phase III studies and some have just been licensed. New oral drugs for MS need to be placed within this evolving marketplace where ease of delivery together with efficacy and side effects needs to be balanced against the known issues but also the known long-term safety of standard injectables.

Journal article

Harris AJ, Durrenberger P, Kamel F, Ettorre A, Nicholas R, Malik O, Altmann DMet al., 2010, Investigating the role of natural killer cell subsets in multiple sclerosis, Annual Congress of the British-Society-for-Immunology, Publisher: WILEY-BLACKWELL PUBLISHING, INC, Pages: 125-125, ISSN: 0019-2805

Conference paper

Nicholas R, D'Arcy C, Muraro P, McGuigan C, Malik O, Giannetti P, O'Driscoll Set al., 2010, USING NATALIZUMAB IN HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK, Annual Meeting of the Association-of-British-Neurologists, Publisher: B M J PUBLISHING GROUP, Pages: E53-E53, ISSN: 0022-3050

Conference paper

Friede T, Nicholas R, Stallard N, Todd S, Parsons N, Valdes-Marquez E, Chataway Jet al., 2010, Refinement of the Clinical Scenario Evaluation Framework for Assessment of Competing Development Strategies With an Application to Multiple Sclerosis, DRUG INFORMATION JOURNAL, Vol: 44, Pages: 713-718, ISSN: 0092-8615

Journal article

Nicholas R, Young C, Friede T, 2010, Bladder symptoms in multiple sclerosis: a review of pathophysiology and management, EXPERT OPINION ON DRUG SAFETY, Vol: 9, Pages: 905-915, ISSN: 1474-0338

Journal article

Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, Aloisi F, Reynolds Ret al., 2010, A Gradient of Neuronal Loss and Meningeal Inflammation in Multiple Sclerosis, ANNALS OF NEUROLOGY, Vol: 68, Pages: 477-493, ISSN: 0364-5134

Journal article

Mattoscio M, Nicholas R, Malik O, Mc Guigan C, Dazzi F, Muraro PAet al., 2010, Functional relevance of haematopoietic stem cell mobilization following therapeutic alpha 4-integrin blockade in multiple sclerosis: preliminary data, 20th Meeting of the European-Neurological-Society, Publisher: SPRINGER HEIDELBERG, Pages: S221-S221, ISSN: 0340-5354

Conference paper

Anderson JM, Patani R, Reynolds R, Nicholas R, Compston A, Spillantini MG, Chandran Set al., 2010, Abnormal tau phosphorylation in primary progressive multiple sclerosis, ACTA NEUROPATHOLOGICA, Vol: 119, Pages: 591-600, ISSN: 0001-6322

Journal article

Politis M, Giannetti P, Su P, Turkheimer F, Keihaninejad S, Wu K, Waldman A, Reynolds R, Nicholas R, Piccini Pet al., 2010, Cortical Microglial Activation Is Associated with Disability in Secondary Progressive Multiple Sclerosis: An In Vivo Imaging Study, 62nd Annual Meeting of the American-Academy-of-Neurology, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: A290-A290, ISSN: 0028-3878

Conference paper

Nicholas R, Radotra B, Roncaroli F, Reynolds Ret al., 2010, Increasing Macroscopic Pathological Damage in Multiple Sclerosis (MS) Is Associated with More Severe Disease Milestones, 62nd Annual Meeting of the American-Academy-of-Neurology, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: A365-A365, ISSN: 0028-3878

Conference paper

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: id=00412643&limit=30&person=true&page=6&respub-action=search.html